Prognostic effect of Epidermal Growth Factor Receptor gene mutations and the aberrant phosphorylation of Akt and ERK in ovarian cancer

Cancer Biology and Therapy

Volumn 11, Issue 1, 2011, Pages 50-57

  Tanaka, Yoshimichi ^a   Terai, Yoshito ^a   Tanabe, Akiko ^a   Sasaki, Hiroshi ^a   Sekijima, Tatsuharu ^a   Fujiwara, Satoe ^a   Yamashita, Yoshiki ^a   Kanemura, Masanori ^a   Ueda, Masatsugu ^b   Sugita, Michio ^c   Franklin, Wilbur A ^c   Ohmichi, Masahide ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

^b Osaka Cancer Prevention and Detection Center   (Japan)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

EGFR mutation; EGFR protein; Gefitinib; Immunohistochemistry; Ovarian cancer; PAkt; PERK; Platinum; Prognostic factor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; MITOGEN ACTIVATED PROTEIN KINASE; PLATINUM; PROTEIN KINASE B;

ADENOCARCINOMA; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CONTROLLED STUDY; ENDOMETRIUM CARCINOMA; GENE MUTATION; GENE SEQUENCE; HUMAN; IMMUNOHISTOCHEMISTRY; JAPANESE; MAJOR CLINICAL STUDY; MUCINOUS CARCINOMA; MULTIVARIATE ANALYSIS; OVARY CANCER; OVERALL SURVIVAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SEROSA;

DISEASE-FREE SURVIVAL; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MULTIVARIATE ANALYSIS; MUTATION; OVARIAN NEOPLASMS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 78751505463     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.11.1.13877     Document Type: Article

References (34)

1. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, et al. Cancer statistics. CA Cancer J Clin 2004; 54:8-29.
2. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995; 19:183-232.
3. Berchuck A, Rodriguez GC, Kamel A, Dodge RK, Soper JT, Clarke-Pearson DL, et al. Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. I. Correlation of receptor expression with prognostic factors in patients with ovarian cancer. Am J Obstet Gynecol 1991; 164:669-74.
4. Lassus H, Sihto H, Leminen A, Joensuu H, Isola J, Nupponen NN, et al. Gene amplification, mutation and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma. J Mol Med 2006; 84:671-81.
5. Psyrri A, Kassar M, Yu Z, Bamias A, Weinberger PM, Markakis S, et al. Effect of epidermal growth factor receptor expression level on survival in patients with epithelial ovarian cancer. Clin Cancer Res 2005; 11:8637-43.
6. Stadlmann S, Gueth U, Reiser U, Diener PA, Zeimet AG, Wight E, et al. Epithelial growth factor receptor status in primary and recurrent ovarian cancer. Mod Pathol 2006; 19:607-10.
7. Douillard JY, Shepherd FA, Hirsh V, Mok T, Socinski MA, Gervais R, et al. Molecular predictors of outcome with Gefitinib and Docetaxel in previously treated nonsmall-cell lung cancer: data from the randomized phase III interest trial. J Clin Oncol 2010; 28:744-52.
8. Lara-Guerra H, Waddell TK, Salvarrey MA, Joshua AM, Chung CT, Paul N, et al. Phase II study of preoperative gefitinib in clinical stage I non-small-cell lung cancer. J Clin Oncol 2009; 27:6229-36.
9. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350:2129-39.
10. Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304:1497-500.
11. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004; 101:13306-11.
12. Hosokawa S, Toyooka S, Fujiwara Y, Tokumo M, Soh J, Takigawa N, et al. Comprehemsive analysis of EGFR signaling pathways in Japanese patients with non-small cell lung cancer. Lung Cancer 2009; 66:107-13.
13. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non-small cell lung cancer with mutated EGFR. N Engl J Med 2010; 362:2380-8.
14. Lacroix L, Pautier P, Duvillard P, Motté N, Saulnier P, Bidart JM, et al. Response of ovarian carcinomas to gefitinib-carboplatin-paclitaxel combination is not associated with EGFR kinase domain somatic mutations. Int J Cancer 2006; 118:1068-9.
15. Mustea A, Sehouli J, Fabjani G, Koensgen D, Möbus V, Braicu EI, et al. Epidermal growth factor receptor (EGFR) mutation does not correlate with platinum resistance in ovarian carcinoma. Results of a prospective pilot study. Anticancer Res 2007; 27:1527-30.
16. Schilder RJ, Sill MW, Chen X, Darcy KM, Decesare SL, Lewandowski G, et al. Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study. Clin Cancer Res 2005; 11:5539-48.
17. Bunn PA Jr, Franklin W. Epidermal growth factor receptor expression, signal pathway and inhibitors in non-small cell lung cancer. Semin Oncol 2002; 29:38-44.
18. Cappuzzo F, Magrini E, Ceresoli GL, Bartolini S, Rossi E, Ludovini V, et al. Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 2004; 96:1133-41.
19. Han SW, Kim TY, Hwang PG, Jeong S, Kim J, Choi IS, et al. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 2005; 23:2493-501.
20. Hirsch FR, Varella-Garcia M, Bunn PA Jr, Franklin WA, Dziadziuszko R, Thatcher N, et al. Molecular predictors of outcome with gefitinib in a phase III palacebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol 2006; 24:5034-42.
21. Cappuzzo F, Ligorio C, Jänne PA, Toschi L, Rossi E, Trisolini R, et al. Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial. J Clin Oncol 2007; 25:2248-55.
22. International Federation of Gynaecology and Obstetrics. Changes in definitions of clinical staging for carcinoma of the cervix and ovary. Am J Obstet Gynecol 1987; 156:263-4.
23. Scully RE, (Ed). Histological typing of ovarian tumours. In International Histological Classification of Tumours, World Health Organization, Berlin, Springer 2004; 11-9.
24. Elie C, Geay JF, Morcos M, Le Tourneau A, Girre V, Broët P, et al. Lack of relationship between EGFR-1 immunohistochemical expression and prognosis in a multicentre clinical trial of 93 patients with advanced primary ovarian epithelial cancer (GINECO group). Br J Cancer 2004; 91:470-5.
25. Nielsen JS, Jakobsen E, Holund B, Bertelsen K, Jakobsen A. Prognostic significance of p53, Her-2 and EGFR overexpression in borderline and epithelial ovarian cancer. Int J Gynecol Cancer 2004; 14:1086-96.
26. Klapper LN, Kirschbaum MH, Sela M, Yarden Y. Biochemical and clinical implications of the ErbB/ HER signaling network of growth factor receptors. Adv Cancer Res 2000; 77:25-79
27. Altomare DA, Wang HQ, Skele KL, De Rienzo A, Klein-Szanto AJ, Godwin AK, et al. AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene 2004; 23:5853-7.
28. Guo RX, Qiao YH, Zhou Y, Li LX, Shi HR, Chen KS. Increased staining for phosphorylated AKT and nuclear factor-kappaB p65 and their relationship with prognosis in epithelial ovarian cancer. Pathol Int 2008; 58:749-56.
29. Yang L, Dan HC, Sun M, Liu Q, Sun XM, Feldman RI, et al. Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt. Cancer Res 2004; 64:4394-9.
30. Mabuchi S, Ohmichi M, Kimura A, Hisamoto K, Hayakawa J, Nishio Y, et al. Inhibition of phosphorylation of BAD and Raf-1 by Akt sensitizes human ovarian cancer cells to paclitaxel. J Biol Chem 2002; 277:33490-500.
31. Mabuchi S, Ohmichi M, Nishio Y, Hayasaka T, Kimura A, Ohta T, et al. Inhibition of inhibitor of nuclear factor-kappaB phosphorylation increases the efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Clin Cancer Res 2004; 10:7645-54.
32. Ohmichi M, Hayakawa J, Tasaka K, Kurachi H, Murata Y. Mechanisms of platinum drug resistance. Trends Pharmacol Sci 2005; 26:113-6.
33. Ohta T, Ohmichi M, Hayasaka T, Mabuchi S, Saitoh M, Kawagoe J, et al. Inhibition of phosphatidylinositol 3-kinase increases efficacy of cisplatin in in vivo ovarian cancer models. Endocrinology 2006; 147:1761-9.
34. Janmaat ML, Kruyt FA, Rodriguez JA, Giaccone G. Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways. Clin Cancer Res 2003; 9:2316-26.